In a groundbreaking development for brain-computer interface (BCI) technology, Synchron Inc., a notable rival to Elon Musk's Neuralink startup, has announced its intention to recruit patients for a large-scale clinical trial. This trial is a crucial step in seeking commercial approval for its innovative brain implant device. The announcement comes as Synchron gears up to further test the efficacy and safety of its Stentrode system, which aims to restore motor functions in patients suffering from severe paralysis.
Synchron's CEO, Thomas Oxley, revealed to Reuters that the company plans to launch an online registry on Monday, April 8, 2024, to facilitate the recruitment process for the upcoming trial. This registry aims to attract patients who are paralyzed due to neurodegenerative diseases like ALS (amyotrophic lateral sclerosis), as well as stroke and multiple sclerosis. The trial is set to include dozens of participants and has garnered interest from about 120 clinical trial centers.
Synchron's approach to brain-computer interface technology is unique. Unlike Neuralink's method, which requires surgical implantation directly into the brain cortex, Synchron's Stentrode device is delivered through a large vein that sits next to the motor cortex in the brain. This minimally invasive procedure significantly reduces the risks associated with traditional brain surgeries.
The Stentrode system has already been tested in a limited number of patients. Synchron has reported no serious adverse side effects in the preliminary testing done in Australia. The company is now analyzing data from the U.S. to prepare for the large-scale trial, which is expected to provide more comprehensive insights into the device's safety and effectiveness.
Synchron's device aims to enable paralyzed patients to interact with digital devices using their thoughts, offering a potential pathway to restore a measure of independence for individuals with severe motor impairments. The company's ambitious goal is to provide patients with the ability to perform tasks such as sending emails, engaging in online banking, and participating in telehealth visits using only their thoughts.
As Synchron readies for this pivotal trial, the company has also received a significant vote of confidence from prominent investors, including Jeff Bezos and Bill Gates. These endorsements underscore the promise and potential impact of Synchron's technology in the field of neurotechnology.
The upcoming large-scale clinical trial represents a crucial milestone not only for Synchron but for the broader field of brain-computer interface technology. If successful, it could pave the way for Synchron's Stentrode system to become commercially available, offering a life-changing solution for individuals living with paralysis.